Pirfenidone attenuates fibrosis by downregulating compounds such as transforming growth factor beta (TGF-β) and has reduced the rate of lung function decline for IPF patients in three phase III clinical trials [3,4,5,6]. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.